Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)21.44bn
- Net income in DKK2.69bn
- Incorporated1950
- Employees5.50k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
Mergers & acquisitions
| Acquired company | HLUN B:CPH since announced | Transaction value |
|---|---|---|
| Longboard Pharmaceuticals Inc | -7.21% | 2.63bn |
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Oct 2024 | 8.98m | 1.13% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 8.75m | 1.10% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 7.47m | 0.94% |
| Polar Capital LLPas of 30 Sep 2024 | 5.00m | 0.63% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 4.42m | 0.56% |
| Skagen AS (Investment Management)as of 30 Sep 2024 | 4.07m | 0.51% |
| Schroder Investment Management Ltd.as of 30 Sep 2024 | 3.82m | 0.48% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 3.77m | 0.47% |
| Lannebo Fonder ABas of 30 Sep 2024 | 3.27m | 0.41% |
| Bankinter Gesti�n de Activos SA SGIICas of 30 Jun 2024 | 3.03m | 0.38% |
